Is MIRA PHARMACEUTICALS, INC. (MIRA) Halal?

NASDAQ Healthcare United States $43M
✓ HALAL
Confidence: 95/100
MIRA PHARMACEUTICALS, INC. (MIRA) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.0% against the AAOIFI threshold of 30%, MIRA PHARMACEUTICALS, INC. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Drug Manufacturers - General), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
5.8%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.0%
/ 33%
5.8%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 0.0%
/ 33%
96.9%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
5.8%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 0.0%
/ 33%
96.9%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.60
P/B Ratio
5.4
Revenue
$0
Beta
1.8
High volatility
Current Ratio
90.5

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -123.3%
Return on Assets (ROA) -74.6%

Cash Flow & Balance Sheet

Operating Cash Flow-$6M
Free Cash Flow-$6M
Total Debt$0
Current Ratio90.5
Total Assets$3M

Price & Trading

Last Close$1.06
50-Day MA$1.22
200-Day MA$1.39
Avg Volume152K
Beta1.8
52-Week Range
$0.73
$2.45

About MIRA PHARMACEUTICALS, INC. (MIRA)

CEO
Mr. Erez Aminov
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Exchange
NASDAQ
Market Cap
$43M
Currency
USD

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is MIRA PHARMACEUTICALS, INC. (MIRA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), MIRA PHARMACEUTICALS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is MIRA PHARMACEUTICALS, INC.'s debt ratio?

MIRA PHARMACEUTICALS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are MIRA PHARMACEUTICALS, INC.'s key financial metrics?

MIRA PHARMACEUTICALS, INC. has a market capitalization of $43M. Return on equity stands at -123.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.